Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04688190 · ClinicalTrials.gov registry record

CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry

A clinical trial of Mitral Regurgitation, sponsored by Universitätsklinikum Hamburg-Eppendorf.

Recruiting
Registry status
800
Enrollment target
20
Study locations

NCT04688190: Recruiting study of Mitral Regurgitation, sponsored by Universitätsklinikum Hamburg-Eppendorf.

NCT04688190 is a study of Mitral Regurgitation that is actively recruiting participants, run by Universitätsklinikum Hamburg-Eppendorf. The registered enrollment target is 800 participants, below the 993-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04688190, a study of Mitral Regurgitation, is actively recruiting participants, sponsored by Universitätsklinikum Hamburg-Eppendorf.

RECRUITING
Registry status
800 participants
Enrollment target
20
Study locations

Study Summary

This multinational, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent transcatheter mitral valve implantation (TMVI), in comparison to those screened for TMVI but deemed ineligible, who subsequently underwent interventional mitral valve edge-to-edge repair, mitral valve surgery or medical/conservative therapy.

Primary Outcome

Mitral insufficiency measured by transthoracic echocardiography. Assessment of MI severity according to current guidelines (ESC/EACTS and ACC/AHA) for valvular heart disease.

Conditions Studied

Study Locations (20)

Other

  • St Vincent's Hospital - Sydney
  • Toronto Heart Center - Toronto
  • St. Paul's Hospital - Vancouver
  • Rigshospitalet - Copenhagen
  • CHU Bordeaux - Bourdeaux
  • Lille University Hospital - Lille
  • Civils Hospices of Lyon - Lyon
  • Clinique Pasteur - Toulouse
  • HDZ Bad Oeynhausen - Bad Oeynhausen
  • German Heart Center Berlin - Berlin
  • Heart Center Bonn - Bonn
  • University Hospital of Cologne - Cologne
  • Goethe-Universität - University Hospital Frankfurt - Frankfurt
  • University Heart and Vascular Center Hamburg - Hamburg
  • Heart Center of the University Medical Center Mainz - Mainz
  • German Heart Centre Munich - Munich
  • LMU Munich - Munich

California

  • Cedars-Sinai Medical Center, Los Angeles - Los Angeles

Massachusetts

  • Brigham and Women's Hospital - Boston

Texas

  • Houston Methodist Hospital - Houston

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2020-11-01
Est. Completion 2030-12-31

What NCT04688190 shows while recruiting

NCT04688190 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 993-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target (19% lower).

The record links to 1 condition, with Mitral Regurgitation appearing as the primary indexed condition, and to 0 interventions.

NCT04688190 names 20 study sites across 4 states, led by Other, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04688190 about?

NCT04688190 is a clinical study titled "CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry". This multinational, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent transcatheter mitral valve implantation (TMVI), in comparison to those screened for TMVI but deemed ineligible, who subsequently underwent interventional mitral valve edge-to-edge ...

What is the current status of trial NCT04688190?

This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2020-11-01. Estimated completion is 2030-12-31.

What conditions does trial NCT04688190 study?

This clinical trial studies the following conditions: Mitral Regurgitation.

Who is sponsoring clinical trial NCT04688190?

This trial is sponsored by Universitätsklinikum Hamburg-Eppendorf, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04688190 being conducted?

This trial has 20 study locations across California, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mitral Regurgitation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04688190's enrollment target sits among peer trials

800 9th of 26 higher than 18 of 26 other Mitral Regurgitation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mitral Regurgitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00695214 · 800 participants · Phase 2

    Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea

  • NCT03048201 · 800 participants · NA

    Physica System Total Knee Replacement Registry Study

  • NCT03792659 · 800 participants

    The EXPLORE MG Registry for Myasthenia Gravis

  • NCT03819296 · 800 participants · Phase 1

    Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04688190, the US trial registry maintained by the National Library of Medicine. NCT04688190 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.